Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: Global research trends, key themes, and emerging frontiers

被引:0
作者
Zuo, Chun-Jian [1 ]
Tian, Jie [2 ,3 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, 1 Youyi Rd, Chongqing 400010, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China
关键词
Lung cancer; apoptosis; immunotherapy; bibliometric analysis; research trends; CELL-DEATH; T-CELLS; INHIBITORS; RESISTANT; THERAPY; CHEMOTHERAPY; NIVOLUMAB; MECHANISM; EFFICACY; BLOCKADE;
D O I
10.1080/21645515.2025.2488074
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Apoptosis is vital for improving the efficacy of lung cancer (LC) immunotherapy by targeting cancer cell elimination. Despite its importance, there is a lack of comprehensive bibliometric studies analyzing global research on apoptosis in LC immunotherapy. This analysis aims to address this gap by highlighting key trends, contributors, and future directions. A total of 969 publications from 1996 to 2024 were extracted from the Web of Science Core Collection. Analysis was conducted using VOSviewer, CiteSpace, and the R package 'bibliometrix.' The study included contributions from 6,894 researchers across 1,469 institutions in 61 countries, with research published in 356 journals. The volume of publications has steadily increased, led by China and the United States, with Sichuan University as the top contributor. The journal Cancers published the most articles, while Cancer Research had the highest co-citations. Yu-Quan Wei was the leading author, and Jemal, A. was the most frequently co-cited. Key research themes include "cell death mechanisms," "immune regulation," "combination therapies," "gene and nanomedicine applications," and "traditional Chinese medicine (TCM)." Future research is likely to focus on "coordinated regulation of multiple cell death pathways," "modulation of the tumor immune microenvironment," "optimization of combination therapies," "novel strategies in gene regulation," and the "integration of TCM" for personalized treatment. This is the first bibliometric analysis on the role of apoptosis in LC immunotherapy, providing an landscape of global research patterns and emerging therapeutic strategies. The findings offer insights to guide future research and optimize treatment approaches.
引用
收藏
页数:22
相关论文
共 137 条
  • [31] Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death
    Gammon, Seth T.
    Engel, Brian J.
    Gores, Gregory J.
    Cressman, Erik
    Piwnica-Worms, David
    Millward, Steven W.
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2020, 22 (05) : 1310 - 1323
  • [32] Biosynthetic MnSe nanobomb with low Mn content activates the cGAS-STING pathway and induces immunogenic cell death to enhance antitumour immunity
    Gao, Wenjuan
    Wang, Yue
    Wang, Peng
    Kan, Wenjie
    Wang, Miaomiao
    Li, Huimin
    Wang, Xiaofei
    Yuan, Pengjun
    Ma, Yuhan
    Zhang, Jia
    Tian, Geng
    Zhang, Guilong
    [J]. ACTA BIOMATERIALIA, 2024, 184 : 383 - 396
  • [33] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
    Garassino, Marina C.
    Gadgeel, Shirish
    Speranza, Giovanna
    Felip, Enriqueta
    Esteban, Emilio
    Domine, Manuel
    Hochmair, Maximilian J.
    Powell, Steven F.
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Kurata, Takayasu
    Gray, Jhanelle E.
    Schwarzenberger, Paul
    Jensen, Erin
    Pietanza, M. Catherine
    Rodriguez-Abreu, Delvys
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 1992 - +
  • [34] Pulmonary toxicity of immune checkpoint immunotherapy
    Ghanbar, Mohammad I.
    Suresh, Karthik
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (02)
  • [35] Targeting apoptosis pathways in cancer therapy
    Ghobrial, IM
    Witzig, TE
    Adjei, AA
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (03) : 178 - 194
  • [36] Mechanisms underlying immunosuppression by regulatory cells
    Goldmann, Oliver
    Nwofor, Obiageli Vivian
    Chen, Qian
    Medina, Eva
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [37] Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic
    Grover, Amit
    Sanseviero, Emilio
    Timosenko, Elina
    Gabrilovich, Dmitry, I
    [J]. CANCER DISCOVERY, 2021, 11 (11) : 2693 - 2706
  • [38] Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI [10.1038/nnano.2010.231, 10.1038/NNANO.2010.231]
  • [39] Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
    Han, Xiao
    Guo, Jun
    Li, Lingyu
    Huang, Yong
    Meng, Xue
    Wang, Linlin
    Zhu, Hui
    Meng, Xiangjiao
    Shao, Qian
    Li, Xing
    Zhang, Yan
    Wang, Jin
    Chen, Yanhua
    Zhang, Yingjie
    Chen, Yiru
    Zhu, Changbin
    Wang, Zhehai
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [40] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
    Haratani, Koji
    Hayashi, Hidetoshi
    Chiba, Yasutaka
    Kudo, Keita
    Yonesaka, Kimio
    Kato, Ryoji
    Kaneda, Hiroyasu
    Hasegawa, Yoshikazu
    Tanaka, Kaoru
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    [J]. JAMA ONCOLOGY, 2018, 4 (03) : 374 - 378